Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

Myriad Genetics (MYGN) stock was upgraded to Overweight by Piper Sandler, citing a balanced risk-reward set up for its beaten ...

Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.

Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral ...

Piper Sandler upgraded Myriad Genetics (MYGN) to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more ...

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Burning Rock Biotech Limited’s BNR share price has dipped by 13.43%, which has investors questioning if this is right time to buy.

Shared investments between research institutions and the government are essential for the health, prosperity and future of ...

Whenever we spoke, there was something medically wrong,” the pal said of the “Gossip Girl” star’s health “curveballs.” ...

A massive study of fraternal and identical twins has surprisingly concluded that much of our emotional response toward dogs is genetic.

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective decreased by Bank of America from $13.00 to $11.00 in ...